Retatrutide
In simple terms, retatrutide helps the body: eat less, burn more calories, lose weight more effectively.
Product Details
| Parameter | Specification |
| Purity | ≥ 99% (HPLC, third-party tested) |
| Form | Lyophilized peptide powder |
| Content | 10 mg Retatrutide per vial |
| Packaging | Glass vial with sterile closure |
| Storage Conditions | Store lyophilized at 2–8 °C (desiccated, protect from light) |
| Molecular Formula | C221H342N46O68 |
| Molecular Weight | ~4731.4 g·mol⁻¹ |
| Amino Acid Sequence | Multidomain incretin/glucagon analog (GIP/GLP-1/glucagon triple agonist) peptide backbone with C20 fatty diacid and γGlu–(AEEA)₂ side chain for extended pharmacokinetics (Retatrutide, LY3437943) |
| CAS Number | 2381089-83-2 |
| Solubility | Bacteriostatic water |
Overview
Retatrutide is a next-generation synthetic peptide classified as a triple incretin receptor agonist, targeting: GLP-1 receptor, GIP receptor, glucagon receptor. It represents a major advancement beyond GLP-1 and dual agonists by incorporating glucagon signaling into metabolic regulation (Jastreboff et al., 2023).
What it is and how it works
Retatrutide combines three mechanisms: GLP-1 (reduces appetite, increases insulin, slows digestion), GIP (enhances insulin response, improves fat metabolism), and Glucagon receptor (increases energy expenditure, stimulates fat burning, promotes thermogenesis). Key innovation: reduced intake + increased energy expenditure (Coskun et al., 2022).
Effects confirmed by research
1. Weight loss
- up to ~20–24% reduction (Jastreboff et al., 2023).
2. Increased energy expenditure
- higher calorie burning, enhanced fat oxidation.
3. Glycemic control
- improved insulin sensitivity.
4. Fat reduction
- decreased visceral fat.
5. Liver effects
- reduced liver fat.
Scientific description
Retatrutide is: a triple GLP-1/GIP/Glucagon receptor agonist, regulator of: appetite, metabolism, energy expenditure.
References
Jastreboff, A. M., et al. Retatrutide for obesity. NEJM. 2023. Coskun, T., et al. Triple agonist mechanisms. Cell Metabolism. 2022. Drucker, D. J. Incretin therapy advances. 2023. Holst, J. J., Rosenkilde, M. M. Incretin biology. Physiological Reviews.
